Research location
Bobigny
Seine-Saint-Denis, France
Advertisement
Research activity in Bobigny
Seine-Saint-Denis, FranceCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bobigny
8 linked trials · page 1 of 1Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]NCT04564547 · 2021-03-09 · 1 site observation
COMPLETED
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)NCT04380636 · 2020-07-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)NCT04233216 · 2020-03-18 · 1 site observation
COMPLETED
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)NCT04233879 · 2020-02-28 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)NCT03425643 · 2018-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical ParkinsonismNCT04948684 · 2017-09-01 · 1 site observation
COMPLETED
Airway and/or Pulmonary Vessels TransplantationNCT01331863 · 2011-05-31 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.